


A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain

Judit Riera-Arnau,^{1,2} Daniel Wang,^{1,2} Jordi Mollet,³ Lucía Bellas,^{1,2} Ricardo Boy,¹ Carlos González-Cruz,³ Mònica Sabaté,^{1,2} Elena Ballarín,¹ Vicenç García-Patos,³ Glòria Aparicio³


¹Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona; ²Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona; ³Department of Dermatology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut De Recerca, Vall d'Hebron Barcelona Campus Hospitalari, Barcelona, Spain

SUPPLEMENTARY MATERIAL


Supplementary Figure 1. Switching patient pathways by biological medicine and treatment line.




Supplementary Figure 2. PASI score evolution overall by biological.



Supplementary Figure 3. PASI score evolution by biological medicine and line of treatment.



Supplementary Figure 4. PASI score evolution by biological, stratified by therapeutic target.



Supplementary Table 1. Anatomical Therapeutic Chemical code classification of biological medicines with the first year of marketing in Spain and the year of approval for psoriasis by the European Medicines Agency.

Drugs	ATC code	Year of first marketing in Spain [§]	Year of approval for psoriasis by the EMA
Infliximab	L04AB02	1999	28/07/2005
Etanercept	L04AB01	2000	29/07/2004
Adalimumab	L04AB04	2003	20/12/2007
Ustekinumab	L04AC05	2009	15/01/2009
Certolizumab	L04AB05	2009	07/12/2018
Secukinumab	L04AC10	2015	14/01/2015
Ixekizumab	L04AC13	2016	25/04/2016
Guselkumab	L04AC16	2017	10/11/2017
Brodalumab	L04AC12	2017	17/07/2017
Tildrakizumab	L04AC17	2018	17/09/2018
Risankizumab	L04AC18	2019	26/04/2019

ATC, Anatomical Therapeutic Chemical code; EMA, European Medicines Agency; [§]Biological medicines might have been marketed for other indications than psoriasis.

Supplementary Table 2. Number and proportion of patients who receive each type of biological medicine used by line and total.

Biological medicine n (%)	Total	1st Line	2nd Line	3rd Line	4th Line	5th Line
Adalimumab	31 (25.2)	21 (36.2)	9 (25.7)	0 (0.0)	1 (11.1)	0 (0.0)
Etanercept	17 (13.8)	16 (27.6)	0 (0.0)	0 (0.0)	1 (11.1)	0 (0.0)
Guselkumab	8 (6.5)	0 (0.0)	4 (11.4)	2 (10.0)	2 (22.2)	0 (0.0)
Infliximab	3 (2.4)	1 (1.7)	1 (2.9)	1 (5.0)	0 (0.0)	0 (0.0)
Ixekizumab	9 (7.3)	0 (0.0)	4 (11.4)	1 (5.0)	3 (33.3)	1 (100)
Risankizumab	4 (3.3)	0 (0.0)	2 (5.7)	2 (10.0)	0 (0.0)	0 (0.0)
Secukinumab	18 (14.6)	6 (10.3)	6 (17.1)	5 (25.0)	1 (11.1)	0 (0.0)
Ustekinumab	32 (26.0)	14 (24.1)	9 (25.7)	8 (40.0)	1 (11.1)	0 (0.0)
Brodalumab	1 (0.8)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)
Total	123	58	35	20	9	1